Cargando…

Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients

The preexistence of humoral immunity, which cross-reacts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein due to prior endemic low-pathogenic human coronavirus infection, has been reported, but its role in coronavirus disease 2019 (COVID-19) outcomes remains elusive. We eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Taro, Shimakami, Tetsuro, Nio, Kouki, Terashima, Takeshi, Okajima, Masaki, Taniguchi, Takumi, Wada, Takashi, Honda, Masao, Gabata, Toshifumi, Ota, Kenji, Yanagihara, Katsunori, Kaneko, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267280/
https://www.ncbi.nlm.nih.gov/pubmed/35807155
http://dx.doi.org/10.3390/jcm11133870
_version_ 1784743680560594944
author Yamashita, Taro
Shimakami, Tetsuro
Nio, Kouki
Terashima, Takeshi
Okajima, Masaki
Taniguchi, Takumi
Wada, Takashi
Honda, Masao
Gabata, Toshifumi
Ota, Kenji
Yanagihara, Katsunori
Kaneko, Shuichi
author_facet Yamashita, Taro
Shimakami, Tetsuro
Nio, Kouki
Terashima, Takeshi
Okajima, Masaki
Taniguchi, Takumi
Wada, Takashi
Honda, Masao
Gabata, Toshifumi
Ota, Kenji
Yanagihara, Katsunori
Kaneko, Shuichi
author_sort Yamashita, Taro
collection PubMed
description The preexistence of humoral immunity, which cross-reacts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein due to prior endemic low-pathogenic human coronavirus infection, has been reported, but its role in coronavirus disease 2019 (COVID-19) outcomes remains elusive. We evaluated serum samples obtained from 368 patients before the pandemic and 1423 independent serum samples from patients during the pandemic. We found that approximately 6~13% and 1.5% of patients had IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in both cohorts. We evaluated the IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in 48 severe or critical COVID-19 patients to evaluate if the elevation of IgG was evoked as a primary response (IgG elevation from 10 days after antigen exposure) or boosted as a secondary response (IgG elevation immediately after antigen exposure). Approximately 50% of patients showed humoral immune responses to the nucleocapsid protein of SARS-CoV-2. Importantly, none of the critically ill patients with this humoral immunity died, whereas 40% of patients without this immunity did. Taken together, subjects had humoral immunity to SARS-CoV-2 nucleocapsid but not spike before the pandemic, which might prevent critically ill COVID-19 patients from dying.
format Online
Article
Text
id pubmed-9267280
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92672802022-07-09 Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients Yamashita, Taro Shimakami, Tetsuro Nio, Kouki Terashima, Takeshi Okajima, Masaki Taniguchi, Takumi Wada, Takashi Honda, Masao Gabata, Toshifumi Ota, Kenji Yanagihara, Katsunori Kaneko, Shuichi J Clin Med Article The preexistence of humoral immunity, which cross-reacts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein due to prior endemic low-pathogenic human coronavirus infection, has been reported, but its role in coronavirus disease 2019 (COVID-19) outcomes remains elusive. We evaluated serum samples obtained from 368 patients before the pandemic and 1423 independent serum samples from patients during the pandemic. We found that approximately 6~13% and 1.5% of patients had IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in both cohorts. We evaluated the IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in 48 severe or critical COVID-19 patients to evaluate if the elevation of IgG was evoked as a primary response (IgG elevation from 10 days after antigen exposure) or boosted as a secondary response (IgG elevation immediately after antigen exposure). Approximately 50% of patients showed humoral immune responses to the nucleocapsid protein of SARS-CoV-2. Importantly, none of the critically ill patients with this humoral immunity died, whereas 40% of patients without this immunity did. Taken together, subjects had humoral immunity to SARS-CoV-2 nucleocapsid but not spike before the pandemic, which might prevent critically ill COVID-19 patients from dying. MDPI 2022-07-04 /pmc/articles/PMC9267280/ /pubmed/35807155 http://dx.doi.org/10.3390/jcm11133870 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamashita, Taro
Shimakami, Tetsuro
Nio, Kouki
Terashima, Takeshi
Okajima, Masaki
Taniguchi, Takumi
Wada, Takashi
Honda, Masao
Gabata, Toshifumi
Ota, Kenji
Yanagihara, Katsunori
Kaneko, Shuichi
Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
title Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
title_full Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
title_fullStr Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
title_full_unstemmed Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
title_short Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
title_sort preexisting humoral immunity cross-reacting with sars-cov-2 might prevent death due to covid-19 in critical patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267280/
https://www.ncbi.nlm.nih.gov/pubmed/35807155
http://dx.doi.org/10.3390/jcm11133870
work_keys_str_mv AT yamashitataro preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT shimakamitetsuro preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT niokouki preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT terashimatakeshi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT okajimamasaki preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT taniguchitakumi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT wadatakashi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT hondamasao preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT gabatatoshifumi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT otakenji preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT yanagiharakatsunori preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients
AT kanekoshuichi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients